阅读说明：本技术 人心果萃取物用于制备调控基因表现量的医药组合物的用途 (Application of human heart fruit extract in preparing medicine composition for regulating gene expression amount ) 是由 林咏翔 林于婷 于 2018-08-06 设计创作，主要内容包括：本发明涉及人心果萃取物的用途,尤其是人心果萃取物用于制备调控基因表现量的组合物的用途。本发明提供一种人心果萃取物用于调控NOS基因、EDN基因、IL基因、VCAM基因、CASP基因、PDGF基因、FGF基因、IGF2BP3基因、IGF1R基因、凝血因子基因、及SERPINE基因表现量的医药组合物的用途,能有效改善血压的调控、降低血管的发炎、减少血管的增生、及预防血栓的形成,以达到心血管保健的功效。其中该人心果萃取物,是人心果以水、醇、或醇水混合物的溶剂所萃取而得。(The invention relates to application of a human heart fruit extract, in particular to application of the human heart fruit extract in preparing a composition for regulating and controlling gene expression amount. The invention provides application of a human heart fruit extract in a medicinal composition for regulating and controlling the expression quantity of NOS (nitric oxide synthase) gene, EDN (adenosine triphosphate) gene, IL (insulin-derived growth factor) gene, VCAM (VCAM) gene, CASP (cysteine-related protein) gene, PDGF (PDGF) gene, FGF (fibroblast growth factor) gene, IGF2BP3 gene, IGF1R gene, blood coagulation factor gene and SERPINE (serine-serine) gene, which can effectively improve the regulation and control of blood pressure, reduce inflammation of blood vessels, reduce the hyperplasia of the blood vessels and prevent the formation of thrombus so as to achieve. Wherein the extract of human heart fruit is obtained by extracting human heart fruit with a solvent selected from water, alcohol, or a mixture of alcohol and water.)

1. A human heart fruit extract is used for preparing a pharmaceutical composition for regulating Nitric Oxide Synthase (NOS) gene, Endothelin (EDN) gene, Interleukin (IL) gene, Vascular Cell Adhesion Molecule (VCAM) gene, Caspase (CASP) gene, Platelet-derived factor (PDGF) gene, Fibroblast Growth Factor (FGF) gene, Insulin growth factor 2mRNA binding protein 3 (Insulin-dependent growth factor 2mRNA-binding protein 3, IGF2BP3) gene, Insulin-like growth factor 1 receptor (IGF 1R) gene, cytokine (cytokine) gene, serine protease inhibitor or serine protease inhibitor, wherein the extract is obtained by extracting a pharmaceutical composition of a human heart fruit extract, the solvent is water, alcohol or alcohol-water mixture, the liquid-solid ratio of the solvent to the naseberry is 2-10: 1-5, and the extraction step is carried out at 75-95 ℃ for 0.5-2 hours.

2. The use of claim 1, wherein the NOS gene is a Nitric oxide synthase 3(Nitric oxide synthase 3, NOS3) gene, the EDN gene is an Endothelin 1(Endothelin 1, EDN1) gene, the IL gene comprises an Interleukin 6(Interleukin 6, IL-6) gene and an Interleukin 8(Interleukin 8, IL-8) gene, the VCAM gene is a Vascular cell adhesion molecule-1 (Vascular adhesion molecule-1, VCAM-1) gene, the CASP gene is a Caspase 8(Caspase 8, CASP8) gene, the PDGF gene is a Platelet-derived growth factor C (PDGFC) gene, the FGF gene is a fibroblast growth factor 2(fibroblast growth factor 2, FGF2) gene, the thrombin-derived growth factor III (Coulogen 383, Coulogen 3) gene, and the thrombin-related protease (serine protease III) gene, SERPINE 1).

3. The use of claim 2, wherein the NOS3 gene is up regulated and the EDN1 gene, IL-8 gene, IL-6 gene, VCAM-1 gene, CASP8 gene, PDGFC gene, FGF2 gene, IGF2BP3 gene, IGF1R gene, F3 gene and SERPINE1 gene are down regulated.

4. Use according to claim 1, wherein the concentration of the extract of human heart fruits is at least 0.0078125 mg/mL.

5. The use according to claim 1, wherein the pharmaceutical composition has a blood pressure regulating function of promoting vasodilation and inhibiting vasoconstriction.

6. The use according to claim 1, wherein the pharmaceutical composition has a function of inhibiting vascular endothelial cell inflammation.

7. The use according to claim 1, wherein the pharmaceutical composition has a function of inhibiting vascular proliferation.

8. The use according to claim 1, wherein the pharmaceutical composition has a function of inhibiting thrombosis.

9. The use of claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

10. Use according to claim 1, characterized in that the pharmaceutical composition is in the form of a powder, granulate, liquid, gel or paste.

Technical Field

The invention relates to application of a human heart fruit extract, in particular to application of a human heart fruit extract in a medical composition for regulating and controlling expression levels of NNOS genes, EDN genes, IL genes, VCAM genes, CASP genes, PDGF genes, FGF genes, IGF2BP3 genes, IGF1R genes, blood coagulation factor genes and SERPINE genes.

Background

Relevant literature statistics show that about one third of the world's population dies of Cardiovascular diseases (CVD), which are also called circulatory diseases, and are caused by organs and tissues that transport blood in the human body, so that all heart and blood vessel diseases can be called Cardiovascular diseases, such as stroke, myocardial infarction, etc.

The drugs for treating cardiovascular diseases are mainly obtained by chemical synthesis and can be divided into two main groups: the first is the medicine for preventing thrombus and platelet coagulation, and the second is the medicine for controlling hypertension, cholesterol and diabetes, however, the two medicines are accompanied by strong side effects. For example, angiotensin-related antagonists may cause hyperkalemia, resulting in muscle weakness or bradycardia; or Statins drugs (HMG-CoA reductaseinhibitors) which are powerful cholesterol-lowering drugs can cause the liver function index to rise or have side effects such as headache, nausea, tiredness and the like. Moreover, these drugs must be taken for a long time to control the disease condition, but the side effects caused by the long-term taking of the drugs on the individual cannot fundamentally improve the physical health of the individual.

In view of the above, there is a need for a pharmaceutical composition comprising active ingredients of natural plants, which can effectively prevent cardiovascular diseases and prevent the side effects of synthetic drugs on the human body, in response to the high incidence of cardiovascular diseases, the improvement of the living level of modern people and the improvement of health care concepts.

Disclosure of Invention

Accordingly, an object of the present invention is to provide a use of a human heart fruit extract for preparing a composition for regulating and controlling the amounts of Nitric Oxide Synthase (NOS) gene, Endothelin (EDN) gene, Interleukin (IL) gene, Vascular Cell Adhesion Molecule (VCAM) gene, Caspase (CASP) gene, Platelet-derived factor (PDGF) gene, Fibroblast Growth Factor (FGF) gene, Insulin-growth factor 2mRNA-binding protein 3(Insulin-like growth factor 2mRNA-binding protein 3, IGF2BP3) gene, Insulin-like growth factor 1 receptor (Insulin-like growth factor 1 receptor, IGF1R) gene, thrombin (kinase) gene, and serine protease (serine) expression, wherein the naseberry extract is obtained by extracting naseberry with a solvent, the solvent is water, alcohol, or a mixture of alcohol and water, the liquid-solid ratio of the solvent to the naseberry is 2-10: 1-5, and the extraction step is carried out at 75-95 ℃ for 0.5-2 hours.

In one embodiment of the present invention, wherein the NOS gene is a Nitric oxide synthase 3 (NOS 3) gene, the EDN gene is an Endothelin 1 (EDN 1) gene, the IL gene comprises an Interleukin 6 (IL-6) gene and an Interleukin 8 (IL-8) gene, the VCAM gene is a Vascular cell adhesion molecule-1 (Vascular cell adhesion protein-1, VCAM-1) gene, the CASP gene is a Caspase 8(Caspase 8, CASP8) gene, the PDGF gene is a Platelet-derived growth factor C (PDGFC) gene, the FGF gene is a Fibroblast growth factor 2(Fibroblast 2, FGF 54) gene, the Coagustin gene is a Coagustin 3 (Coagustin 3) gene, the Coagustin gene is a Coalbumin-6 (endothelial 1, EDN1) gene, the IL gene comprises a Interleukin 6 (IL-6 ) gene and a Interleukin 8 (IL-8 ) gene, the VCAM gene is a Vascular adhesion molecule-1 (Vascular cell adhesion molecule-1, the PDGFC) gene, the FGF gene is a Fibroblast growth factor 2(Fibroblast growth factor III) gene, the Coagustin III gene is a Fibroblast growth factor III, the Coagustin III (PIE-family 1) gene, SERPINE 1).

In one embodiment of the present invention, the NOS3 gene is up-regulated, and the EDN1 gene, IL-8 gene, IL-6 gene, VCAM-1 gene, CASP8 gene, PDGFC gene, FGF2 gene, IGF2BP3 gene, IGF1R gene, F3 gene and SERPINE1 gene are down-regulated.

In one embodiment of the present invention, the concentration of the human heart fruit extract is at least 0.0078125mg/mL, and the pharmaceutical composition has the functions of regulating blood pressure, inhibiting vascular endothelial cell inflammation, inhibiting vascular proliferation and inhibiting thrombosis, which can promote vasodilation and inhibit vasoconstriction.

Meanwhile, the pharmaceutical composition for regulating the expression level of the NOS3 gene, the EDN1 gene, the IL-8 gene, the IL-6 gene, the VCAM-1 gene, the CASP8 gene, the PDGFC gene, the FGF2 gene, the IGF2BP3 gene, the IGF1R gene, the F3 gene and the SERPINE1 gene can also comprise an effective amount of the human heart fruit extract and a pharmaceutically acceptable carrier, and the composition is in a powdery, granular, liquid, colloidal or paste form.

Therefore, the human heart fruit extract can effectively improve the regulation and control of blood pressure, reduce the generation of vascular inflammation, reduce the proliferation of blood vessels and prevent the formation of thrombus, so that the human heart fruit extract can be used as a raw material of a cardiovascular health-care product, can achieve the effects of improving the regulation and control of blood pressure, reducing the vascular inflammation, reducing the vascular proliferation and reducing the formation of thrombus for people with potential risks, and can comprehensively prevent the occurrence of atherosclerosis so as to achieve the effect of cardiovascular health care.

The following description of the present invention is provided in connection with the accompanying drawings, which are included to illustrate and not to limit the scope of the present invention, and it will be understood by those skilled in the art that various changes and modifications may be made therein without departing from the spirit and scope of the invention, and it is intended to cover all modifications and equivalents as may fall within the true spirit and scope of the invention.

Drawings

FIG. 1 is a histogram of the expression level of human heart fruit extract in promoting NOS3 gene and reducing EDN1 gene, p value < 0.05; p value < 0.001;

FIG. 2 is a histogram of the expression level of the human heart fruit extract of the present invention in reducing the expression levels of IL-8 gene, IL-6 gene, VCAM-1 gene, CASP8 gene, with a value of p < 0.01; p value < 0.001;

FIG. 3 is a histogram of the expression of human heart fruit extract of the present invention in decreasing PDGFC gene, FGF2 gene, IGF2BP3 gene, IGF1R gene with p value < 0.05; p value < 0.01; p value < 0.001;

fig. 4 is a histogram of the reduction of F3 gene expression and SERPINE1 gene expression of human heart fruit extracts of the invention, with values of p < 0.001.

Detailed Description

As used herein, the numerical values are approximations and all numerical data are reported to be within the 20 percent range, preferably within the 10 percent range, and most preferably within the 5 percent range.